Entire COX-2 Class Is TARGET Of Critical Lancet Editorial
This article was originally published in The Pink Sheet Daily
Executive Summary
The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.